Cytokinetics (CYTK)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$74.11-1.65%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Cytokinetics launched its heart drug Myqorzo in Germany. Revenue is expected near $830M to $870M in 2026. The company aims to control operating expenses better. Analysts expect revenue growth of about 22% next year.
The company is still losing money with negative EPS. Operating expenses remain high with limited progress. Revenue growth is slow and missed targets recently.
The price is about 26% below our fair value near $112. The market expects 22% revenue growth, which matches analysts' views.
Breaks if: Operating income worse than -$183.6 million in FY26
Focus on controlling and reducing operating expenses to improve financial performance.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making but is focused on launching its product MYQORZO and advancing its clinical development for aficamten.
The market appears to be pricing in a stretched valuation compared to peers, reflecting a low expectations gap. There is a sense of fragility in the current setup, as the company has not yet established strong momentum.
Management is on track with its priorities, particularly in commercial launch and market expansion. However, clinical development progress is mixed, and recent financial performance has been below industry peers, which could pose risks.
The long-term thesis hinges on the successful commercial launch of MYQORZO and advancements in clinical trials for aficamten. Additionally, the performance of sector bellwethers and overall market conditions will play a crucial role.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports the thesis. The company reached a Phase 3 milestone for aficamten. This advance helps clinical development and regulatory approvals. There are no new threats to the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Myqorzo sales fail to grow or decline materially
Breaks if: Revenue falls below $830 million in FY26
Over the next 1 to 3 years, CYTK's trajectory will depend on its ability to manage risks and execute its strategic priorities effectively. Not investment advice.